Merck & Co., Inc. Available-for-sale Securities, Amortized Cost Basis
Merck & Co., Inc. (MRK) had Available-for-sale Securities, Amortized Cost Basis of $15.24 billion as of 2017-12-31, per its 10-K filed 2019-02-27.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2019-02-27
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $15.24B.
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $16.00B.
- 2017-06-30: Available-for-sale Securities, Amortized Cost Basis $17.05B.
- 2017-03-31: Available-for-sale Securities, Amortized Cost Basis $16.22B.
| Period end | Available-for-sale Securities, Amortized Cost Basis | Available-for-sale Securities, Amortized Cost Basis as first filed |
|---|---|---|
| 2017-12-31 | $15.24B 10-K · filed 2019-02-27 | |
| 2017-09-30 | $16.00B 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $17.05B 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $16.22B 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $20.16B 10-K · filed 2018-02-27 | |
| 2016-09-30 | $17.69B 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $17.92B 10-Q · filed 2016-08-08 | |
| 2016-03-31 | $15.82B 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $18.02B 10-K · filed 2017-02-28 | |
| 2015-09-30 | $17.70B 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $17.78B 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $20.69B 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $21.86B 10-K · filed 2016-02-26 | |
| 2014-09-30 | $16.60B 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $16.37B 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $16.32B 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $11.79B 10-K · filed 2015-02-27 | |
| 2013-09-30 | $13.46B 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $11.79B 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $11.06B 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $10.12B 10-K · filed 2014-02-27 | |
| 2012-09-30 | $6.41B 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $4.89B 10-Q · filed 2012-08-07 | |
| 2012-03-31 | $5.01B 10-Q · filed 2012-05-08 | |
| 2011-12-31 | $5.04B 10-K · filed 2013-02-28 | |
| 2011-09-30 | $3.90B 10-Q · filed 2011-11-08 | |
| 2011-06-30 | $3.98B 10-Q · filed 2011-08-08 | |
| 2011-03-31 | $3.57B 10-Q · filed 2011-05-09 | |
| 2010-12-31 | $3.61B 10-K · filed 2012-02-28 | |
| 2010-09-30 | $3.10B 10-Q · filed 2010-11-08 | |
| 2010-06-30 | $3.56B 10-Q · filed 2010-08-06 | |
| 2009-12-31 | $924.00M 10-K · filed 2011-02-28 | $923.80M 10-Q · filed 2010-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |